Results 201 to 210 of about 76,403 (315)

Sperm protein 17 (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk [PDF]

, 2001
Maurizio Chiriva‐Internati, Zhiqing Wang, Yuying Xue, Klaus Bumm, Amy B. Hahn, Seah H. Lim   +5 more
openalex   +1 more source

Biomarkers of Cellular Senescence in Type 2 Diabetes Mellitus

Aging Cell, EarlyView.
In cohorts of lean controls, obese participants without Type 2 Diabetes Mellitus (T2DM) and obese T2DM participants, we find that T‐cell expression of senescence biomarkers is altered only in the T2DM participants and not with obesity alone. Moreover, high T‐cell p16 expression in the T2DM participants is associated with impaired bone cortical indices.
Caroline Hoong, Joshua N. Farr, David G. Monroe, Thomas A. White, Elizabeth J. Atkinson, Amanda Tweed, Allyson K. Palmer, Nathan K. LeBrasseur, Jad G. Sfeir, Sundeep Khosla   +9 more
wiley   +1 more source

Protein kinase C δ and η isoenzymes control the shedding of the interleukin 6 receptor α in myeloma cells [PDF]

, 2001
Wilfrid Thabard, M. Collette, Régis Bataille, Martine Amiot   +3 more
openalex   +1 more source

PROTEINS IN MULTIPLE MYELOMA

Journal of Biological Chemistry, 1953
Frank W. Putnam, Bernard Udin
openaire   +3 more sources

Zosteriform Primary Cutaneous Marginal Zone Lymphoma—A Case Report

Australasian Journal of Dermatology, EarlyView.
ABSTRACT We report a case of zosteriform PCMZL presenting in a T3–T4 dermatomal distribution not previously described in the literature. Although the varicella zoster virus was not detected in this case, late diagnosis of the acute eruption of zoster or even preceding zoster ‘sine herpete’ cannot be excluded as antigenic triggers.
Natalie Teh, Lachlan Byth, Victor Loh, Mrudula Krishnaswamy, Samuel Zagarella   +4 more
wiley   +1 more source

Decoding multiple myeloma: single-cell insights into tumor heterogeneity, immune dynamics, and disease progression. [PDF]

Front Immunol
Zhao Z, Zhao Z, Lin Z, Fan L, Xiahou Z, Dong Y, Bao W.   +6 more
europepmc   +1 more source

A case of visceral leishmaniasis mimicking connective tissue disease

Rheumatology &Autoimmunity, EarlyView.
Yucui Li, Hongxia Yang, Tingzi Zhao, Ke Xu, Liyun Zhang   +4 more
wiley   +1 more source

Can we identify individuals at risk to develop multiple myeloma? A machine learning‐based predictive model

British Journal of Haematology, EarlyView.
Individuals who may develop multiple myeloma within 5 years. Stage I (left) identifies patient and control groups and variables that differ between them. Stage II (middle) develops a complex SGBOOST model to predict future MM patients. Stage III (right) develops a simplified model.
Moshe Mittelman, Ariel Israel, Howard S. Oster, Michael Leshchinsky, Yatir Ben‐Shlomo, Eldad Kepten, Osnat Jarchowsky Dolberg, Ran Balicer, Galit Shaham   +8 more
wiley   +1 more source

Silymarin induces multiple myeloma cell apoptosis by inhibiting the JAK2/STAT3 signaling pathway. [PDF]

Oncol Lett
Liu H, Liu T, Zeng J, Fang Q.
europepmc   +1 more source

Mapping VEXAS‐associated and rare UBA1 variants in the United Kingdom: Insights from patient cohorts and the general population

British Journal of Haematology, EarlyView.
VEXAS syndrome is a late‐onset inflammatory disorder with rheumatological and haematological features. Epidemiological studies of VEXAS syndrome so far have been limited. Analysis of various UK cohorts estimates the incidence of VEXAS to be 1.51/100 000, or 171 new cases in the population of men over the age of 50 who are being investigated for myeloid
Ana Martinez Rodriguez, Leon Chang, Dorota Rowczenio, Alexandra Smith, Ebun Omoyinmi, James A. Poulter, Andrew McGregor, Sebastian Francis, Roochi Trikha, Adam Al‐Hakim, Kar Lok Kong, David G. Kent, Helen Lachmann, Austin Kulasekararaj, Catherine Cargo, Sinisa Savic   +15 more
wiley   +1 more source